查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1813461

2032 年癌症倖存者管理市场预测：按组件、部署模式、癌症类型、最终用户和地区进行的全球分析

Cancer Survivorship Management Market Forecasts to 2032 - Global Analysis By Component (Services, Software & Digital Platforms and Other Components), Deployment Mode, Cancer Type, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球癌症生存管理市场预计在 2025 年达到 22.9 亿美元，预计到 2032 年将达到 44.8 亿美元，预测期内的复合年增长率为 10.0%。

癌症存活管理是一种结构化的多学科护理，从确诊到治疗后，为患者提供持续的照顾。该护理包括復发监测、治疗的长期和长期影响管理、促进身心健康以及协调后续护理。此方法也应对社会、经济和生活方式方面的挑战，同时为看护者提供支持。生存计画旨在恢復生活质量，促进患者重返社会，并确保医疗保健提供者提供持续的照顾。

根据《血液学与肿瘤学杂誌》报道，到2021年，癌症将占全球男性和女性死亡人数的14.57%，占总伤残调整生命年（DALY）的8.8%。年龄标准化发生率（ASIR）为每10万人790.33例，其中女性的ASIR高于男性（923.44 vs. 673.09），而男性的年龄标准化死亡率（ASDR）更高（145.69 vs. 93.60），这凸显了製定性别敏感的癌症控制策略的必要性。

提高对近期和长期影响的认识

医疗保健提供者如今优先考虑长期监测和復健策略，以应对疲劳、认知能力下降和继发性恶性肿瘤等问题。这种转变推动了对超越急性护理的综合生存护理计划的需求。此外，数据分析和病患登记系统的进步使得更好地追踪存活结果成为可能，并促进了循证干预措施的实施。随着全球存活率的提高，结构化追踪护理的需求正成为肿瘤服务的核心重点。

护理分散且不协调，报销不足

倖存者经常在缺乏集中护理协调的专家之间辗转，导致症状管理和心理社会支持方面存在差异。不同地区的倖存者服务报销政策不一致，阻碍了医疗机构投资于综合计画。此外，缺乏标准化的长期追踪通讯协定也导致了护理品质的差异。这些机构效率低下的问题阻碍了倖存者模式的扩充性，并减缓了市场扩张。

专注于预防和健康计划

融合营养咨询、身体復健、心理健康支持和生活方式调整的项目越来越受欢迎。数位平台和行动医疗应用程式促进了个人化的健康追踪，使倖存者能够积极管理自己的康復情况。此外，雇主和保险公司也越来越多地支持倖存者健康倡议，以降低长期医疗成本。这种积极主动的方法正在将倖存者照护从被动治疗转变为促进整体健康。

治疗抵抗和劳动力短缺

某些癌症治疗方案的抗药性正在出现，对有效的生存管理构成威胁，尤其是在需要长期治疗的病例中。随着癌症类型的演变和日益复杂，对专业后续护理的需求也日益增长。然而，训练有素的肿瘤学专业人员和生存护理专家的短缺正给医疗保健系统带来巨大压力。农村和服务欠缺地区尤其脆弱，难以获得多学科团队的帮助。这种需求和人力的不平衡可能会危及生存服务的品质和范围。

COVID-19的影响：

由于医疗系统优先考虑紧急应变，COVID-19疫情扰乱了常规癌症治疗，包括癌症倖存者服务。许多倖存者的后续预约、筛检和復健治疗都遭遇延误，导致焦虑加剧，症状难以控制。同时，这场危机加速了远端医疗和远端监控工具的普及，这些工具如今已成为癌症倖存者照护的必需品。虚拟支援小组和数位护理协调平台应运而生，填补了这些空白，在封锁期间提供了持续的护理。

服务业预计将成为预测期内最大的产业

预计服务领域将在预测期内占据最大市场份额，这得益于其提供全面的咨询、康復、营养支持和长期监测服务。这些服务对于满足倖存者从身体康復到心理健康等多方面的需求至关重要。医院和专科诊所正在扩展倖存者计划，以纳入由电子健康记录和患者参与工具支援的个人化护理途径。

预计骨髓恶性肿瘤领域在预测期内将达到最高复合年增长率

预计骨髓恶性肿瘤领域将在预测期内达到最高成长率。由于復发和免疫系统併发症的风险较高，白血病、淋巴瘤和骨髓瘤的倖存者通常需要在治疗后接受密切监测。标靶治疗和干细胞移植的创新提高了生存率，增加了对计划生存护理的需求。此外，对长期血液毒性和继发性癌症的研发正在推动专门的追踪通讯协定的发展，进一步推动该领域的成长。

占比最高的地区：

预计亚太地区将在预测期内占据最大的市场份额，这得益于其庞大的患者群体和不断扩展的医疗基础设施。中国、印度和日本等国家正大力投资肿瘤服务，包括整合存活期照护。公共卫生宣传活动和政府资助的措施正在提高人们对治疗后支持的认识，而私人医疗机构也在推出专为癌症倖存者量身定制的健康中心。

复合年增长率最高的地区：

预计北美在预测期内的复合年增长率最高，这得益于其先进的医疗保健体系和以患者为中心的医疗服务。美国和加拿大在实施生存照顾计画方面处于主导，并得到了政策框架和报销模式的支持。学术机构和癌症中心正在进行关于存活结果的开创性研究，影响临床指南和治疗标准。

免费客製化服务：

此报告的订阅者可以使用以下免费自订选项之一：

  • 公司简介
    • 对最多三家其他市场公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球癌症倖存者管理市场（按组成部分）

  • 服务
    • 后续行动和监测
    • 症状管理
    • 社会心理与心理健康支持
    • 营养咨询
    • 身体復健和运动计划
    • 生育治疗和性健康管理
  • 软体和数位平台
    • 带有重要模组的电子健康记录（EHR）
    • 患者门户网站和行动应用程式
    • 护理协调和导航工具
    • 远端医疗和远端监控解决方案
  • 其他组件

6. 全球癌症生存管理市场（依部署模式）

  • 云端基础/SaaS
  • 本地部署
  • 杂交种

7. 全球癌症生存管理市场（按癌症类型）

  • 乳癌
  • 摄护腺癌
  • 大肠直肠癌
  • 造血系统恶性肿瘤
  • 其他癌症类型

8. 全球癌症倖存者管理市场（按最终用户）

  • 医院和癌症中心
  • 门诊手术中心（ASC）
  • 居家照护环境
  • 专科诊所
  • 其他最终用户

9. 全球癌症倖存者管理市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十章：重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • Elekta AB
  • Accuray Incorporated
  • Varian Medical Systems
  • Philips Healthcare
  • GE Healthcare
  • Roche
  • Novartis AG
  • Bristol-Myers Squibb（BMS）
  • Pfizer Inc.
  • Johnson & Johnson
  • Guardant Health
  • Illumina
  • McKesson Corporation
  • Allscripts Healthcare Solutions, Inc.
  • Epic Systems Corporation
  • Cerner Corporation
  • Carevive Systems
  • Cordata Healthcare Innovations
Product Code: SMRC30910

According to Stratistics MRC, the Global Cancer Survivorship Management Market is accounted for $2.29 billion in 2025 and is expected to reach $4.48 billion by 2032 growing at a CAGR of 10.0% during the forecast period. Cancer survivorship management is the structured, multidisciplinary care provided to individuals from the point of diagnosis through post-treatment life. It encompasses monitoring for recurrence, managing long-term and late effects of therapy, promoting physical and psychological well-being, and coordinating follow-up care. This approach also addresses social, financial, and lifestyle challenges while supporting caregivers. Survivorship plans aim to restore quality of life, facilitate reintegration, and ensure continuity of care across healthcare providers

According to Journal of Hematology & Oncology, cancer accounted for 14.57% of global deaths and 8.8% of total disability-adjusted life years (DALYs) in 2021 across both sexes. The age-standardized incidence rate (ASIR) was 790.33 per 100,000, with females exhibiting higher ASIR than males (923.44 vs. 673.09), while males showed higher age-standardized death rates (ASDR) (145.69 vs. 93.60), underscoring the need for gender-sensitive cancer control strategies.

Market Dynamics:

Driver:

Growing recognition of late and long-term effects

Healthcare providers are now prioritizing long-term monitoring and rehabilitation strategies to address issues such as fatigue, cognitive decline, and secondary malignancies. This shift is driving demand for integrated survivorship care plans that extend beyond acute treatment. Moreover, advancements in data analytics and patient registries are enabling better tracking of survivorship outcomes, fostering evidence-based interventions. As survivorship rates improve globally, the need for structured follow-up care is becoming a central focus in oncology services.

Restraint:

Fragmented and uncoordinated care, inadequate reimbursement

Survivors often navigate multiple specialists without cohesive care coordination, leading to gaps in symptom management and psychosocial support. Reimbursement policies for survivorship services remain inconsistent across regions, discouraging providers from investing in comprehensive programs. Additionally, the lack of standardized protocols for long-term follow-up contributes to variability in care quality. These systemic inefficiencies hinder the scalability of survivorship models and slow down market expansion.

Opportunity:

Driving focus on preventative and wellness programs

Programs that incorporate nutrition counseling, physical rehabilitation, mental health support, and lifestyle modification are gaining traction. Digital platforms and mobile health applications are facilitating personalized wellness tracking, empowering survivors to actively manage their recovery. Furthermore, employers and insurers are increasingly supporting survivorship wellness initiatives to reduce long-term healthcare costs. This proactive approach is reshaping survivorship care from reactive treatment to holistic health promotion.

Threat:

Therapeutic resistance & workforce shortages

Emerging resistance to certain cancer therapies poses a threat to effective survivorship management, particularly in cases requiring prolonged treatment. As cancer types evolve and become more complex, the need for specialized follow-up care intensifies. However, a shortage of trained oncology professionals and survivorship care specialists is straining healthcare systems. Rural and underserved regions are especially vulnerable, with limited access to multidisciplinary teams. This imbalance between demand and workforce capacity may compromise the quality and reach of survivorship services.

Covid-19 Impact:

The COVID-19 pandemic disrupted routine cancer care, including survivorship services, as healthcare systems prioritized emergency response. Many survivors experienced delays in follow-up appointments, screenings, and rehabilitation therapies, leading to increased anxiety and unmanaged symptoms. On the other hand, the crisis accelerated the adoption of telehealth and remote monitoring tools, which have now become integral to survivorship care. Virtual support groups and digital care coordination platforms emerged to fill the gap, offering continuity of care during lockdowns.

The services segment is expected to be the largest during the forecast period

The services segment is expected to account for the largest market share during the forecast period due to its comprehensive offerings, including counseling, rehabilitation, nutritional support, and long-term monitoring. These services are essential for addressing the multifaceted needs of survivors, ranging from physical recovery to emotional well-being. Hospitals and specialty clinics are expanding survivorship programs to include personalized care pathways, supported by electronic health records and patient engagement tools.

The hematologic malignancies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the hematologic malignancies segment is predicted to witness the highest growth rate. Survivors of leukemia, lymphoma, and myeloma often require intensive post-treatment surveillance due to high relapse risks and immune system complications. Innovations in targeted therapies and stem cell transplantation have improved survival rates, thereby increasing the demand for structured survivorship care. Additionally, research into long-term hematologic toxicity and secondary cancers is driving the development of specialized follow-up protocols, boosting segment growth.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share attributed to its vast patient population and expanding healthcare infrastructure. Countries like China, India, and Japan are investing heavily in oncology services, including survivorship care integration. Public health campaigns and government-backed initiatives are raising awareness about post-treatment support, while private providers are launching wellness centers tailored for cancer survivors.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR driven by its advanced healthcare systems and strong focus on patient-centered care. The U.S. and Canada are leading in the implementation of survivorship care plans, supported by policy frameworks and reimbursement models. Academic institutions and cancer centers are pioneering research on survivorship outcomes, influencing clinical guidelines and care standards.

Key players in the market

Some of the key players in Cancer Survivorship Management Market include Elekta AB, Accuray Incorporated, Varian Medical Systems, Philips Healthcare, GE Healthcare, Roche, Novartis AG, Bristol-Myers Squibb (BMS), Pfizer Inc., Johnson & Johnson, Guardant Health, Illumina, McKesson Corporation, Allscripts Healthcare Solutions, Inc., Epic Systems Corporation, Cerner Corporation, Carevive Systems, and Cordata Healthcare Innovations.

Key Developments:

In July 2025, Novartis announced regulatory approval for the first malaria medicine for newborns and young infants (Coartem(R) baby), marking an important pediatric milestone. The company noted expectation of rapid regulatory approvals in several African countries under a special global pathway. Novartis framed the approval as expanding access for vulnerable, very young patients.

In July 2025, Illumina launched the next generation of TruSight Oncology 500 (announced July 30, 2025), a comprehensive genomic profiling assay for cancer research. The product release highlighted expanded genomic coverage to support research and clinical trial workflows.

In May 2025, Roche announced FDA approval of the VENTANA(R) MET (SP44) RxDx Assay - the first companion diagnostic approved to assess MET protein expression in certain non-small cell lung cancers. The approval enables patient selection for AbbVie's c-Met targeted therapy (Emrelis(TM)) and supports precision oncology pathways.

Components Covered:

  • Services
  • Software & Digital Platforms
  • Other Components

Deployment Modes Covered:

  • Cloud-based / SaaS
  • On-premises
  • Hybrid

Cancer Types Covered:

  • Breast
  • Prostate
  • Colorectal
  • Hematologic malignancies
  • Other Cancer Types

End Users Covered:

  • Hospitals and Cancer Centers
  • Ambulatory Surgical Centers (ASCs)
  • Homecare Settings
  • Specialty Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Cancer Survivorship Management Market, By Component

  • 5.1 Introduction
  • 5.2 Services
    • 5.2.1 Follow-up & Surveillance
    • 5.2.2 Symptom Management
    • 5.2.3 Psychosocial & Mental Health Support
    • 5.2.4 Nutritional Counseling
    • 5.2.5 Physical Rehabilitation & Exercise Programs
    • 5.2.6 Fertility & Sexual Health Management
  • 5.3 Software & Digital Platforms
    • 5.3.1 Electronic Health Records (EHR) with Survivorship Modules
    • 5.3.2 Patient Portals & Mobile Apps
    • 5.3.3 Care Coordination & Navigation Tools
    • 5.3.4 Telehealth & Remote Monitoring Solutions
  • 5.4 Other Components

6 Global Cancer Survivorship Management Market, By Deployment Mode

  • 6.1 Introduction
  • 6.2 Cloud-based / SaaS
  • 6.3 On-premises
  • 6.4 Hybrid

7 Global Cancer Survivorship Management Market, By Cancer Type

  • 7.1 Introduction
  • 7.2 Breast
  • 7.3 Prostate
  • 7.4 Colorectal
  • 7.5 Hematologic malignancies
  • 7.6 Other Cancer Types

8 Global Cancer Survivorship Management Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals and Cancer Centers
  • 8.3 Ambulatory Surgical Centers (ASCs)
  • 8.4 Homecare Settings
  • 8.5 Specialty Clinics
  • 8.6 Other End Users

9 Global Cancer Survivorship Management Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Elekta AB
  • 11.2 Accuray Incorporated
  • 11.3 Varian Medical Systems
  • 11.4 Philips Healthcare
  • 11.5 GE Healthcare
  • 11.6 Roche
  • 11.7 Novartis AG
  • 11.8 Bristol-Myers Squibb (BMS)
  • 11.9 Pfizer Inc.
  • 11.10 Johnson & Johnson
  • 11.11 Guardant Health
  • 11.12 Illumina
  • 11.13 McKesson Corporation
  • 11.14 Allscripts Healthcare Solutions, Inc.
  • 11.15 Epic Systems Corporation
  • 11.16 Cerner Corporation
  • 11.17 Carevive Systems
  • 11.18 Cordata Healthcare Innovations

List of Tables

  • Table 1 Global Cancer Survivorship Management Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Cancer Survivorship Management Market Outlook, By Component (2024-2032) ($MN)
  • Table 3 Global Cancer Survivorship Management Market Outlook, By Services (2024-2032) ($MN)
  • Table 4 Global Cancer Survivorship Management Market Outlook, By Follow-up & Surveillance (2024-2032) ($MN)
  • Table 5 Global Cancer Survivorship Management Market Outlook, By Symptom Management (2024-2032) ($MN)
  • Table 6 Global Cancer Survivorship Management Market Outlook, By Psychosocial & Mental Health Support (2024-2032) ($MN)
  • Table 7 Global Cancer Survivorship Management Market Outlook, By Nutritional Counseling (2024-2032) ($MN)
  • Table 8 Global Cancer Survivorship Management Market Outlook, By Physical Rehabilitation & Exercise Programs (2024-2032) ($MN)
  • Table 9 Global Cancer Survivorship Management Market Outlook, By Fertility & Sexual Health Management (2024-2032) ($MN)
  • Table 10 Global Cancer Survivorship Management Market Outlook, By Software & Digital Platforms (2024-2032) ($MN)
  • Table 11 Global Cancer Survivorship Management Market Outlook, By Electronic Health Records (EHR) with Survivorship Modules (2024-2032) ($MN)
  • Table 12 Global Cancer Survivorship Management Market Outlook, By Patient Portals & Mobile Apps (2024-2032) ($MN)
  • Table 13 Global Cancer Survivorship Management Market Outlook, By Care Coordination & Navigation Tools (2024-2032) ($MN)
  • Table 14 Global Cancer Survivorship Management Market Outlook, By Telehealth & Remote Monitoring Solutions (2024-2032) ($MN)
  • Table 15 Global Cancer Survivorship Management Market Outlook, By Other Components (2024-2032) ($MN)
  • Table 16 Global Cancer Survivorship Management Market Outlook, By Deployment Mode (2024-2032) ($MN)
  • Table 17 Global Cancer Survivorship Management Market Outlook, By Cloud-based / SaaS (2024-2032) ($MN)
  • Table 18 Global Cancer Survivorship Management Market Outlook, By On-premises (2024-2032) ($MN)
  • Table 19 Global Cancer Survivorship Management Market Outlook, By Hybrid (2024-2032) ($MN)
  • Table 20 Global Cancer Survivorship Management Market Outlook, By Cancer Type (2024-2032) ($MN)
  • Table 21 Global Cancer Survivorship Management Market Outlook, By Breast (2024-2032) ($MN)
  • Table 22 Global Cancer Survivorship Management Market Outlook, By Prostate (2024-2032) ($MN)
  • Table 23 Global Cancer Survivorship Management Market Outlook, By Colorectal (2024-2032) ($MN)
  • Table 24 Global Cancer Survivorship Management Market Outlook, By Hematologic malignancies (2024-2032) ($MN)
  • Table 25 Global Cancer Survivorship Management Market Outlook, By Other Cancer Types (2024-2032) ($MN)
  • Table 26 Global Cancer Survivorship Management Market Outlook, By End User (2024-2032) ($MN)
  • Table 27 Global Cancer Survivorship Management Market Outlook, By Hospitals and Cancer Centers (2024-2032) ($MN)
  • Table 28 Global Cancer Survivorship Management Market Outlook, By Ambulatory Surgical Centers (ASCs) (2024-2032) ($MN)
  • Table 29 Global Cancer Survivorship Management Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 30 Global Cancer Survivorship Management Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 31 Global Cancer Survivorship Management Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.